Friday, June 3, 2011

Hurry!

Bioscience Company shows success in animal trials for Factor IX Gene Therapy Treatment
-Sangamo scientist Michael Holmes presented data from a study in mice which showed encouraging results in a specific type of hemophilia. In this case, the disease comes from a deficiency of a protein know as Factor IX. Scientists gave a single injection of one of Sangamo's zinc-finger compounds and found that mice who got the injection were able to produce Factor IX on their own in high enough levels to achieve normal blood clotting...
Original article from Xconomy.com